Structural connectivity networks in prodromal and clinical Huntington’s disease
Objective: To investigate how structural connectivity correlates with the number of CAG repeats, disease evolution and clinical measures in presymptomatic (preHD) and clinical Huntington Disease…Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study
Objective: The Swallowing Disturbance Questionnaire (SDQ) was administered to patients with Huntington disease (HD) as part of a randomized, controlled study of deutetrabenazine for the…Magnetic resonance imaging and pyramidal impairment in Huntington disease
Objective: To identify structural involvement of the corticospinal pathway in Huntington disease (HD) with clinical upper motor neuron signs using diffusion tensor imaging (DTI). Background:…Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the FIRST-HD and TETRA-HD trials
Objective: To compare the tolerability of deutetrabenazine (DTB) and tetrabenazine (TBZ) as observed in the FIRST-HD (NCT01795859) and TETRA-HD (NCT00219804) trials for the treatment of…Clinical and behavioral features in carriers of intermediate length alleles of HTT gene. A case series of Mexican population
Objective: To describe clinical manifestations in carriers of intermediate alleles (IAs) of CAG trinucleotides in HTT gene of Mexican population. Background: Huntington's disease (HD) is…CAG repeat length and weight loss in pre-manifest Huntington’s disease
Objective: To explore if CAG repeat length is a predictor of weight loss in pre-manifest Huntington's disease. Background: Weight loss is a hallmark finding in…Temporal course of the UHDRS chorea score in Huntington disease
Objective: To describe the temporal course of Huntington disease (HD) chorea using the total maximal chorea score of the Unified Huntington Disease Rating Scale -…Psychosis in Huntington’s disease
Objective: To describe the characteristics and phenomenology of psychotic symptoms in a Spanish cohort of HD patients. Background: Neuropsychiatric features are characteristic symptoms in Huntington's…Prospective evaluation of pallidal deep brain stimulation in Huntington’s disease
Objective: To prospectively evaluate the effect of bilateral pallidal deep brain stimulation (DBS) on motor symptoms, activities of daily living and quality of life in…A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval
Objective: Evaluate the pharmacokinetics and pharmacodynamics (QTc) of SD-809 (deutetrabenazine) and tetrabenazine. Background: SD-809 is a VMAT-2 inhibitor in clinical development for treatment of hyperkinetic…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- Next Page »